Naproxen Prodrug Clinical Results Positive

27 May 2009 (Last Updated May 27th, 2009 18:30)

Medinox and Logical Therapeutics have reported positive results for Naproxen Prodrug. LT-NS001 is a novel patented NCE prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen. The drug is being developed to reduce the GI safety risks, including the formation of ulcers, associ

Medinox and Logical Therapeutics have reported positive results for Naproxen Prodrug. LT-NS001 is a novel patented NCE prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen.

The drug is being developed to reduce the GI safety risks, including the formation of ulcers, associated with naproxen.

The trial consisted of a double-blind, randomised, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen in patients aged 45 to 70 years.

During the trial, the patients underwent upper endoscopies at baseline and on day seven. The data showed patients receiving LT-NS001 experienced statistically fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

The company reported no serious adverse events and LT-NS001 was well tolerated.